NO20012017L - Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose - Google Patents

Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Info

Publication number
NO20012017L
NO20012017L NO20012017A NO20012017A NO20012017L NO 20012017 L NO20012017 L NO 20012017L NO 20012017 A NO20012017 A NO 20012017A NO 20012017 A NO20012017 A NO 20012017A NO 20012017 L NO20012017 L NO 20012017L
Authority
NO
Norway
Prior art keywords
vegf
gene
protein
prevent restenosis
growth factor
Prior art date
Application number
NO20012017A
Other languages
English (en)
Other versions
NO20012017D0 (no
Inventor
Kari Alitalo
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20012017D0 publication Critical patent/NO20012017D0/no
Publication of NO20012017L publication Critical patent/NO20012017L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
NO20012017A 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose NO20012017L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (2)

Publication Number Publication Date
NO20012017D0 NO20012017D0 (no) 2001-04-24
NO20012017L true NO20012017L (no) 2001-06-26

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012017A NO20012017L (no) 1998-10-26 2001-04-24 Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (no)
JP (2) JP4769929B2 (no)
CN (1) CN1338943A (no)
AT (1) ATE275417T1 (no)
AU (1) AU768330B2 (no)
CA (1) CA2340593C (no)
DE (1) DE69920031T2 (no)
ES (1) ES2229788T3 (no)
NO (1) NO20012017L (no)
NZ (1) NZ510121A (no)
PT (1) PT1126870E (no)
WO (1) WO2000024412A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
ATE377081T1 (de) 2000-02-25 2007-11-15 Ludwig Inst Cancer Res Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
DE60139471D1 (de) * 2000-06-01 2009-09-17 Univ North Carolina Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
ATE481097T1 (de) * 2001-01-16 2010-10-15 Vascular Therapies Llc Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
EP1499344A1 (en) * 2002-04-30 2005-01-26 FIT Biotech Oyj Plc Medical device
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
WO2005039556A1 (ja) * 2003-10-29 2005-05-06 Institute Of Medicinal Molecular Design. Inc. 血行再建術後の再狭窄又は再閉塞の治療及び／又は予防のための医薬
JP4832290B2 (ja) * 2004-03-18 2011-12-07 健輔 江頭 薬剤・遺伝子溶出型ステント
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
EP2063910A2 (en) 2006-09-22 2009-06-03 Orthologic Corp. Method of treating endothelial dysfunction
CA2715765A1 (en) 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
DK2107109T3 (da) * 1996-08-23 2012-09-24 Vegenics Pty Ltd Rekombinant vaskulær endotelcelle-vækstfaktor D (VEGF-D)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
JP2001524828A (ja) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質

Also Published As

Publication number Publication date
JP5231587B2 (ja) 2013-07-10
CA2340593C (en) 2012-05-08
NZ510121A (en) 2003-02-28
AU1314700A (en) 2000-05-15
ES2229788T3 (es) 2005-04-16
WO2000024412A3 (en) 2000-08-03
AU768330B2 (en) 2003-12-11
PT1126870E (pt) 2005-01-31
EP1126870A2 (en) 2001-08-29
DE69920031T2 (de) 2005-09-22
EP1126870B1 (en) 2004-09-08
JP4769929B2 (ja) 2011-09-07
JP2002528420A (ja) 2002-09-03
DE69920031D1 (de) 2004-10-14
JP2011173874A (ja) 2011-09-08
CA2340593A1 (en) 2000-05-04
NO20012017D0 (no) 2001-04-24
WO2000024412A2 (en) 2000-05-04
ATE275417T1 (de) 2004-09-15
CN1338943A (zh) 2002-03-06

Similar Documents

Publication Publication Date Title
NO20012017D0 (no) Anvendelse av VEGF-C eller VEGF-D gen eller protein for å forebygge restenose
Opperman et al. TGF‐β1, TGF‐β2, and TGF‐β3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro
Hultgårdh-Nilsson et al. Expression of phenotype-and proliferation-related genes in rat aortic smooth muscle cells in primary culture
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
ATE163046T1 (de) Genetische veränderung von endothelzellen
Kallassy et al. Patched (ptch)-associated preferential expression of smoothened (smoh) in human basal cell carcinoma of the skin
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
SE8902532L (sv) Bestaemning av plasmaproteiner
NO881670L (no) Diagnostisk proeve paa inhibitor for plasminogenaktivatorerav vev- og urokinasetype, samt gen som koder for inhibitoren.
EP1023005A4 (en) METHOD FOR COATING STENTS WITH DNA, AND FOR IN VIVO EXPRESSION OF RECOMBINANT GENES OF DNA COATED
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
ATE203766T1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE60035426D1 (de) Genomisches peroxidasegen von ipomea batatas und dessen promotor
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
ES2184059T3 (es) Vector retrovirico y su utilizacion en terapia genica.
Guzman et al. Early and sustained medial cell activation after aortocaval fistula creation in mice
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
BG105682A (en) Bone stimulating factor
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung